An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Issue 4 (3rd February 2017)

• Record Type: Journal Article
• Authors: Poordad, Fred; Lawitz, Eric; Gutierrez, Julio A.; Guerrero, Juan; Speeg, Kermit; Swenson, Eugene S.
• Is Part Of: Clinical case reports. Volume 5:Issue 4(2017)
• Page Start: 371
• Page End: 375
• Publication Date: 2017-02-03
• Subjects: Daclatasvir -- hepatitis C -- liver transplantation -- sofosbuvir; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.841
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: This case suggests that initiation of HCV therapy immediately after liver transplantation with well‐tolerated, all‐oral regimens may achieve a virologic cure in HCV‐positive recipients, thus preventing post‐transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of HCV‐positive donor livers, potentially including HCV‐negative transplant recipients. Abstract : This case suggests that initiation of HCV therapy immediately after liver transplantation with well‐tolerated, all‐oral regimens may achieve a virologic cure in HCV‐positive recipients, thus preventing post‐transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of HCV‐positive donor livers, potentially including HCV‐negative transplant recipients.